ADMA Biologics, Inc. ADMA
Nov 6, 2026, 10:09 AM EST
- YTD
- -29.03%
- 1 year
- -7.73%
- Market cap
- 2.88B
- Revenue (ttm)
- 512.28M
- Profit margin
- 32.98%
- EPS (ttm)
- 0.77
- Shares out
- 223.98M
- P/E ratio
- 16.83
- Forward P/E
- 14.00
- YTD return
- -29.03%
- 1-year return
- -7.73%
- Volume
- 592.07K
- Avg volume
- 3.03M
- Open
- 13.13
- Previous close
- 13.21
- Day's range
- 12.63 – 13.16
- 52-week range
- 7.21 – 20.46
- Beta
- 0.66
- Price target
- 17.00 (+31.3%)
- Earnings date
- Feb 24, 2027
5D +1.59 (+13.95%)
Key statistics
- Enterprise value
- 2.42B
- PEG ratio
- 0.00
- Price / sales
- 5.78
- Price / book
- 6.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2.00%
- Free cash flow
- 54.76M
- Total cash
- 136.02M
- Total debt
- 203.84M
- Return on equity
- 41.90%
- Short % of float
- 10.74%
- 50-day average
- 10.07
- 200-day average
- 10.86
Analyst view
- Target (low)
- 12.00
- Target (mean)
- 17.00
- Target (high)
- 21.00
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.24333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.22 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.1967 | 0.23 | +0.03 | +16.93% |
| Aug 5, 2026 | Jun 30, 2026 | 0.1633 | 0.16 | 0.00 | -2.02% |
| May 6, 2026 | Mar 31, 2026 | 0.1933 | 0.19 | 0.00 | -1.71% |
| Feb 25, 2026 | Dec 31, 2025 | 0.185 | 0.20 | +0.02 | +8.11% |
| Nov 5, 2025 | Sep 30, 2025 | 0.16 | 0.16 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Jul 15, 2026 | Mizuho | main | Outperform | Outperform |
| May 7, 2026 | Canaccord Genuity | main | Buy | Buy |
| May 7, 2026 | Mizuho | main | Outperform | Outperform |
| Apr 21, 2026 | Canaccord Genuity | init | — | Buy |
| Apr 13, 2026 | Mizuho | main | Outperform | Outperform |
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- admabiologics.com
News
12 Health Care Stocks Moving In Thursday's Intraday Session 
ADMA Biologics CEO Says Star Drug ASCENIV Is Just Getting Started 
Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
Cantor Fitzgerald Maintains Neutral on ADMA Biologics, Raises Price Target to $13 
ADMA Biologics (ADMA) Shares Jump 28% After-Hours: Here’s Why 
ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript 
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates 
ADMA Biologics Q3 Earnings Call Highlights
Your note
Sign in to keep a note on ADMA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELMS STEVEN A | Director | Purchase | Mar 5, 2026 | 0 |
| FINGER ALISON CECILY | Director | Stock Award(Grant) | Feb 8, 2026 | 45,619 |
| GROSSMAN ADAM S | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 15, 2026 | 3,837,160 |
| GROSSMAN JERROLD B | Director | Purchase | May 26, 2026 | 612,991 |
| GUIHEEN LAWRENCE P | Director | Stock Gift | Mar 16, 2026 | 186,510 |
| KESTENBERG-MESSINA KAITLIN M. | Officer | Conversion of Exercise of derivative security | Mar 8, 2026 | 466,600 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.12% | 38,355,684 | 506.68M | Jun 29, 2026 |
| State Street Corporation | 7.64% | 17,116,022 | 226.10M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.51% | 10,103,809 | 133.47M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.50% | 10,088,490 | 133.27M | Jun 29, 2026 |
| Rubric Capital Management LP | 4.17% | 9,339,414 | 123.37M | Jun 29, 2026 |
| Capital Research Global Investors | 3.91% | 8,756,374 | 115.67M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 13,332,053 | 176.12M | Sep 29, 2026 |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 4.45% | 9,970,973 | 131.72M | Sep 29, 2026 |
| SmallCap World Fund Inc | 3.81% | 8,524,390 | 112.61M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 7,023,200 | 92.78M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.66% | 5,963,003 | 78.77M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.02% | 4,534,131 | 59.90M | Sep 29, 2026 |